Brainstorm Cell Therapeutics (NASDAQ:BCLI) Downgraded to Sell Rating by StockNews.com

StockNews.com lowered shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) from a hold rating to a sell rating in a report issued on Tuesday.

Brainstorm Cell Therapeutics Stock Down 3.3 %

Shares of Brainstorm Cell Therapeutics stock opened at $1.18 on Tuesday. Brainstorm Cell Therapeutics has a 12-month low of $1.09 and a 12-month high of $11.89. The company has a market capitalization of $6.28 million, a price-to-earnings ratio of -0.34 and a beta of 0.40. The firm’s 50-day moving average price is $2.71 and its two-hundred day moving average price is $4.80.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.60). During the same quarter last year, the business posted ($4.05) EPS. On average, sell-side analysts expect that Brainstorm Cell Therapeutics will post -2.85 earnings per share for the current year.

Institutional Trading of Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Armistice Capital LLC bought a new position in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned approximately 11.30% of Brainstorm Cell Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 14.33% of the company’s stock.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.